[REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN

Summary

Combination therapy using 5α-reductase inhibitors and α-blockers significantly improves quality of life for benign prostatic hyperplasia (BPH) patients. This approach offers better safety, prevents BPH progression, and reduces the need for surgery compared to monotherapy.

Related Concept Videos